NRXP Stock Summary and Trading Ideas (NRX Pharmaceuticals | NASDAQ:NRXP)

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

NRX Pharmaceuticals trades on the NASDAQ stock market under the symbol NRXP.

As of August 28, 2026, NRXP stock price declined to $3.55 with 670,886 million shares trading.

NRXP has a beta of 2.01, meaning it tends to be more sensitive to market movements. NRXP has a correlation of 0.10 to the broad based SPY ETF.

NRXP has a market cap of $153.70 million. This is considered a Micro Cap stock.

Last quarter NRX Pharmaceuticals reported $1 million in Revenue and -$.44 earnings per share. This fell short of revenue expectation by $-442,736 and missed earnings estimates by -$.32.

In the last 3 years, NRXP traded as high as $7.33 and as low as $1.10.

The top ETF exchange traded funds that NRXP belongs to (by Net Assets): VTI, PSIL, VXF, IWC.

NRXP has outperformed the market in the last year with a price return of +40.9% while the SPY ETF gained +19.7%. However, in the short term, NRXP had mixed performance relative to the market. It has underperformed in the last 3 months, returning -20.0% vs +2.2% return in SPY. But in the last 2 weeks, NRXP shares have fared better than the market returning +8.6% compared to SPY -0.9%.

NRXP support price is $3.41 and resistance is $3.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRXP shares will trade within this expected range on the day.